A promising predictive biomarker combined EBV NDA with PNI for nasopharyngeal carcinoma in nonendemic area of China

Qiao He; Yecai Huang; Linjia Yuan; Zuo Wang; Qiuju Wang; Daduan Liu; Luona Li; Xianbing Li; Zhi Cao; Dongsheng Wang; Mu Yang

doi:10.1038/s41598-023-38396-z

Scientific Reports (Jul 2023)

A promising predictive biomarker combined EBV NDA with PNI for nasopharyngeal carcinoma in nonendemic area of China

Qiao He,
Yecai Huang,
Linjia Yuan,
Zuo Wang,
Qiuju Wang,
Daduan Liu,
Luona Li,
Xianbing Li,
Zhi Cao,
Dongsheng Wang,
Mu Yang

Affiliations

Qiao He: School of Medicine, University of Electronic Science and Technology of China
Yecai Huang: Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China
Linjia Yuan: Department of Radiation Oncology, Jinjiang Da Guan Hospital of Chengdu
Zuo Wang: School of Medicine, University of Electronic Science and Technology of China
Qiuju Wang: Department of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China
Daduan Liu: School of Medicine, University of Electronic Science and Technology of China
Luona Li: Department of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China
Xianbing Li: Department of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China
Zhi Cao: Department of Radiation Oncology, Jinjiang Da Guan Hospital of Chengdu
Dongsheng Wang: School of Medicine, University of Electronic Science and Technology of China
Mu Yang: School of Medicine, University of Electronic Science and Technology of China

DOI: https://doi.org/10.1038/s41598-023-38396-z
Journal volume & issue: Vol. 13, no. 1
pp. 1 – 11

Abstract

Read online

Abstract In endemic areas, EBV DNA is used to guide diagnosis, detect recurrence and distant metastasis of NPC. Until now, the importance of EBV DNA in the prediction of NPC has received little attention in non-endemic regions. To explore the prognostic value of EBV DNA alone or in combination with PNI in NPC patients from a non-endemic area of China. In this retrospective study, 493 NPC patients were enrolled. Clinical pathologic data, pre-treatment plasma EBV DNA, and laboratory tests were all performed. A standard anticancer treatment was prescribed, and follow up data were collected. EBV DNA was found to be positively related to clinical stage (r = 0.357, P 262.7 copies/ml group was 88% and 65.3%, respectively (P 0.05). This novel combination biomarker was a promising biomarker for predicting NPC survival and may one day guide treatment option.

Published in Scientific Reports

ISSN: 2045-2322 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Medicine; Science
Website: https://www.nature.com/srep/

About the journal